In the late 1990s Regeneron, the biotechnology company based in Tarrytown, NY, was developing a treatment for amyotrophic lateral sclerosis , better known as Lou Gehrig's disease, which cause paralysis and then death.
http://www.forbes.com/sites/matthewherper/2013/11/12/what-the-delay-of-a-promising-muscular-dystrophy-drug-means-for-patients-investors-and-all-of-biotech/
http://www.forbes.com/sites/matthewherper/2013/11/12/what-the-delay-of-a-promising-muscular-dystrophy-drug-means-for-patients-investors-and-all-of-biotech/
No comments:
Post a Comment